Cargando…

BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy

Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: The optical coherence tomography and best corr...

Descripción completa

Detalles Bibliográficos
Autores principales: Płatkowska-Adamska, Bernadetta, Bociek, Agnieszka, Krupińska, Joanna, Kal, Magdalena, Biskup, Michał, Zarębska-Michaluk, Dorota, Odrobina, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696807/
https://www.ncbi.nlm.nih.gov/pubmed/36366385
http://dx.doi.org/10.3390/vaccines10111878
_version_ 1784838399879806976
author Płatkowska-Adamska, Bernadetta
Bociek, Agnieszka
Krupińska, Joanna
Kal, Magdalena
Biskup, Michał
Zarębska-Michaluk, Dorota
Odrobina, Dominik
author_facet Płatkowska-Adamska, Bernadetta
Bociek, Agnieszka
Krupińska, Joanna
Kal, Magdalena
Biskup, Michał
Zarębska-Michaluk, Dorota
Odrobina, Dominik
author_sort Płatkowska-Adamska, Bernadetta
collection PubMed
description Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: The optical coherence tomography and best corrected visual acuity (BCVA) records of the two previous visits before the first dose of BNT162b2 (first pre-vaccination visit marked as “V-1”, the previous pre-vaccination “V-2”), and two subsequent visits after the second dose of vaccination (first visit after the second dose marked as “V1”, second visit after the second dose marked as “V2”) were collected for 63 eyes of 59 patients. Results: The difference in the average retinal thickness was observed between the last and each other checkpoint for the aflibercept group and in the overall outcome. The maximum thickness from the inner retinal surface to the inner border of RPE decreased during the observation; differences were observed comparing visits −2 and 1. Subretinal complex thickness decreased during follow-up, and the differences were observed between visits −2 and 2. There were no statistically significant differences in the BCVA and the occurrence of intraretinal cystoid fluid, serous PED, subretinal hyperreflective material, and retinal hemorrhage. Conclusion: In the present study, the activity of the exudative form of AMD did not deteriorate after the administration of the BNT162b2 vaccine.
format Online
Article
Text
id pubmed-9696807
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96968072022-11-26 BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy Płatkowska-Adamska, Bernadetta Bociek, Agnieszka Krupińska, Joanna Kal, Magdalena Biskup, Michał Zarębska-Michaluk, Dorota Odrobina, Dominik Vaccines (Basel) Article Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination. Methods: The optical coherence tomography and best corrected visual acuity (BCVA) records of the two previous visits before the first dose of BNT162b2 (first pre-vaccination visit marked as “V-1”, the previous pre-vaccination “V-2”), and two subsequent visits after the second dose of vaccination (first visit after the second dose marked as “V1”, second visit after the second dose marked as “V2”) were collected for 63 eyes of 59 patients. Results: The difference in the average retinal thickness was observed between the last and each other checkpoint for the aflibercept group and in the overall outcome. The maximum thickness from the inner retinal surface to the inner border of RPE decreased during the observation; differences were observed comparing visits −2 and 1. Subretinal complex thickness decreased during follow-up, and the differences were observed between visits −2 and 2. There were no statistically significant differences in the BCVA and the occurrence of intraretinal cystoid fluid, serous PED, subretinal hyperreflective material, and retinal hemorrhage. Conclusion: In the present study, the activity of the exudative form of AMD did not deteriorate after the administration of the BNT162b2 vaccine. MDPI 2022-11-07 /pmc/articles/PMC9696807/ /pubmed/36366385 http://dx.doi.org/10.3390/vaccines10111878 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Płatkowska-Adamska, Bernadetta
Bociek, Agnieszka
Krupińska, Joanna
Kal, Magdalena
Biskup, Michał
Zarębska-Michaluk, Dorota
Odrobina, Dominik
BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
title BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
title_full BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
title_fullStr BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
title_full_unstemmed BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
title_short BNT162b2 (Pfizer/BioNTech) COVID-19 Vaccination Was Not Associated with the Progression of Activity of the Exudative Form of Age-Related Macular Degeneration during Anti-VEGF Therapy
title_sort bnt162b2 (pfizer/biontech) covid-19 vaccination was not associated with the progression of activity of the exudative form of age-related macular degeneration during anti-vegf therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696807/
https://www.ncbi.nlm.nih.gov/pubmed/36366385
http://dx.doi.org/10.3390/vaccines10111878
work_keys_str_mv AT płatkowskaadamskabernadetta bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy
AT bociekagnieszka bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy
AT krupinskajoanna bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy
AT kalmagdalena bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy
AT biskupmichał bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy
AT zarebskamichalukdorota bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy
AT odrobinadominik bnt162b2pfizerbiontechcovid19vaccinationwasnotassociatedwiththeprogressionofactivityoftheexudativeformofagerelatedmaculardegenerationduringantivegftherapy